{"id":8680,"date":"2021-06-09T14:58:23","date_gmt":"2021-06-09T11:58:23","guid":{"rendered":"https:\/\/roboforex.com\/blog\/?p=8680"},"modified":"2023-06-22T17:58:59","modified_gmt":"2023-06-22T14:58:59","slug":"biogen-shares-grew-by-38-after-fda-decision","status":"publish","type":"post","link":"https:\/\/roboforex.com\/blog\/2021\/06\/09\/biogen-shares-grew-by-38-after-fda-decision\/","title":{"rendered":"Biogen Shares Grew by 38% after FDA decision"},"content":{"rendered":"\n

At the beginning of this week, a super important thing happened: For the first time in eighteen years, US authorities approved a drug for curing the Alzheimer’s disease. The shares of Biogen, the company that produces the drug, as well as the shares of other biotech companies headed upwards immediately. Let’s discuss what’s going on with the market and how long it will last.<\/p>\n\n\n\n

<\/span>FDA approved Aduhelm for treating the Alzheimer’s<\/span><\/h2>\n\n\n\n

On June 7th, the US FDA<\/a> approved a drug against Alzheimer’s for the first time since 2003. This drug is Aduhelm (aducanumab) created by an American biotech corporation Biogen.<\/p>\n\n\n\n

The manufacturer is sure that the drug can not only slow down and stanch the development of the disease that destroys memory and cognition skills but also prevent these processes.<\/p>\n\n\n\n

However, note that the regulator requires further studies from Biogen. If the research does not confirm the claimed effect, FDA will forbid selling the drug.<\/p>\n\n\n\n

<\/span>Some details about Aduhelm<\/span><\/h2>\n\n\n\n